Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18976165 | 0.85 | — | — | |
| SCHEMBL18975580 | 0.85 | — | — | |
| SCHEMBL30896150 | 0.79 | FFAR1 (0.33) | LPLLIPGP2RX7 | |
| SCHEMBL22861265 | 0.79 | LPL (0.37) | LPLLIPGP2RX7 | |
| SCHEMBL24616853 | 0.79 | LPL (0.31) | LPLLIPGP2RX7 | |
| SCHEMBL24617151 | 0.79 | CA1 (0.33) | LPLLIPGP2RX7CA1CA2 | |
| SCHEMBL20516993 | 0.78 | LPL (0.30) | LPLLIPGP2RX7 | |
| SCHEMBL20543216 | 0.78 | FFAR1 (0.33) | LPLLIPGP2RX7 | |
| SCHEMBL21382126 | 0.77 | LPL (0.34) | LPLLIPGUCHL1 | |
| SCHEMBL20456084 | 0.75 | LPL (0.31) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4212523-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-12617798-B2 | Imidazopyrazne derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4041731-B1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | INCYTE CORPORATION | 2026-01-22 | — | — | US | disclosed |
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-2027124-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-02-25 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007131991-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | SGK1, PBK, SGK3 | LPL 3228/4885LIPG 3340/4885P2RX7 4088/4885 |
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | LPL 4316/4885LIPG 3293/4885P2RX7 1450/4885 |
| US-20260022119-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | CCNA1, CDK1, CCNE1 | LPL 4316/4885LIPG 4405/4885P2RX7 3906/4885 |
| US-12617798-B2 | Imidazopyrazne derivatives | CLIC1, HCFC1, CXCR1 | LPL 4453/4885LIPG 4382/4885P2RX7 1949/4885 |
| US-20090318425-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | LPL 3473/4885LIPG 2223/4885P2RX7 3923/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | LPL 862/4885LIPG 1472/4885P2RX7 3992/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | LPL 3959/4885LIPG 4317/4885P2RX7 274/4885 |
| US-12466828-B2 | Bicyclic amines as CDK2 inhibitors | CDK2, CDK1, CCNI | LPL 4634/4885LIPG 4423/4885P2RX7 4214/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | LPL 343/4885LIPG 223/4885P2RX7 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.